Clara Alcon
YOU?
Author Swipe
View article: YM155 Inhibition of Survivin Enhances Carboplatin Efficacy in Metastatic Castration-Resistant Prostate Cancer
YM155 Inhibition of Survivin Enhances Carboplatin Efficacy in Metastatic Castration-Resistant Prostate Cancer Open
Background/Objectives: Metastatic castration-resistant prostate cancer (mCRPC) remains a major clinical challenge due to its aggressive behavior and resistance to therapy. Survivin, a member of the inhibitor of apoptosis protein family, is…
View article: Inhibiting <scp>H3K27</scp> Demethylases Downregulates <scp>CREB</scp> ‐ <scp>CREBBP</scp> , Overcoming Resistance in Relapsed Acute Lymphoblastic Leukemia
Inhibiting <span>H3K27</span> Demethylases Downregulates <span>CREB</span> ‐ <span>CREBBP</span> , Overcoming Resistance in Relapsed Acute Lymphoblastic Leukemia Open
Background CREB binding protein (CREBBP) is a key epigenetic regulator, altered in a fifth of relapsed cases of acute lymphoblastic leukemia (ALL). Selectively targeting epigenetic signaling may be an effective novel therapeutic approach t…
View article: HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells
HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells Open
Senescent cells are commonly detected in tumors after chemo and radiotherapy, leading to a characteristic cellular phenotype that resists apoptotic cell death. In this study, we used multiple melanoma cell lines, molecular markers, and the…
View article: HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells.
HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells. Open
Senescent cells are commonly detected in tumors after chemo and radiotherapy, leading to a characteristic cellular phenotype that resists apoptotic cell death. In this study, we used multiple melanoma cell lines, molecular markers, and the…
View article: Identification of GB3 as a Novel Biomarker of Tumor-Derived Vasculature in Neuroblastoma Using a Stiffness-Based Model
Identification of GB3 as a Novel Biomarker of Tumor-Derived Vasculature in Neuroblastoma Using a Stiffness-Based Model Open
Neuroblastoma (NB) is a childhood cancer in sympathetic nervous system cells. NB exhibits cellular heterogeneity, with adrenergic and mesenchymal states displaying distinct tumorigenic potentials. NB is highly vascularized, and blood vesse…
View article: Dual inhibition of MEK and PI3Kβ/δ–a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer
Dual inhibition of MEK and PI3Kβ/δ–a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer Open
Background: Docetaxel remains the standard treatment for metastatic castration-resistant prostate cancer (mCRPC). However, resistance frequently emerges as a result of hyperactivation of the PI3K/AKT and the MEK/ERK pathways. Therefore, th…
View article: Supplemental Text, Supplemental Figures, and Supplemental Tables from Cell Line–Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations
Supplemental Text, Supplemental Figures, and Supplemental Tables from Cell Line–Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations Open
Word file containing the Supplemental Text, Supplemental Figures S1-S6, and Supplemental Tables S1-S2.
View article: Supplemental File 2 from Cell Line–Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations
Supplemental File 2 from Cell Line–Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations Open
Supplemental File 2. Excel file with the cbioportal data the genomic data analysis is based on.
View article: Data from Cell Line–Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations
Data from Cell Line–Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations Open
Durable control of invasive solid tumors necessitates identifying therapeutic resistance mechanisms and effective drug combinations. In this work, we used a network-based mathematical model to identify sensitivity regulators and drug combi…
View article: Supplemental File 1 from Cell Line–Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations
Supplemental File 1 from Cell Line–Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations Open
Supplemental File 1. Excel file with additional details on the mathematical model.
View article: Supplemental File 2 from Cell Line–Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations
Supplemental File 2 from Cell Line–Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations Open
Supplemental File 2. Excel file with the cbioportal data the genomic data analysis is based on.
View article: Data from Cell Line–Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations
Data from Cell Line–Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations Open
Durable control of invasive solid tumors necessitates identifying therapeutic resistance mechanisms and effective drug combinations. In this work, we used a network-based mathematical model to identify sensitivity regulators and drug combi…
View article: Supplemental Text, Supplemental Figures, and Supplemental Tables from Cell Line–Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations
Supplemental Text, Supplemental Figures, and Supplemental Tables from Cell Line–Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations Open
Word file containing the Supplemental Text, Supplemental Figures S1-S6, and Supplemental Tables S1-S2.
View article: Supplemental File 1 from Cell Line–Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations
Supplemental File 1 from Cell Line–Specific Network Models of ER<sup>+</sup> Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations Open
Supplemental File 1. Excel file with additional details on the mathematical model.
View article: BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma
BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma Open
Background Pilocytic astrocytoma (PA) is the most common pediatric brain tumor and a mitogen-activated protein kinase (MAPK)-driven disease. Oncogenic MAPK-signaling drives the majority of cells into oncogene-induced senescence (OIS). Whil…
View article: LGG-18. Inhibition of Bcl-xL targets the senescent compartment of pilocytic astrocytoma
LGG-18. Inhibition of Bcl-xL targets the senescent compartment of pilocytic astrocytoma Open
INTRODUCTION: Pilocytic astrocytoma (PA) is a mitogen-activated protein kinase (MAPK)-driven disease. Treatment of sub-totally resected PA remains challenging and relapses occur even after MAPK-targeted therapies such as MEK inhibition. On…
View article: MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia
MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia Open
Multiple targeted therapies are currently explored for pediatric and young adult B-cell precursor acute lymphoblastic leukemia (BCP-ALL) treatment. However, this new armamentarium of therapies faces an old problem: choosing the right treat…
View article: Cell Line–Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations
Cell Line–Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations Open
Durable control of invasive solid tumors necessitates identifying therapeutic resistance mechanisms and effective drug combinations. In this work, we used a network-based mathematical model to identify sensitivity regulators and drug combi…
View article: ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins
ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins Open
Breast cancer is the most frequent type of cancer and the major cause of mortality in women. The rapid development of various therapeutic options has led to the improvement of treatment outcomes; nevertheless, one-third of estrogen recepto…
View article: Cell line-specific network models of ER+ breast cancer identify PI3Kα inhibitor sensitivity factors and drug combinations
Cell line-specific network models of ER+ breast cancer identify PI3Kα inhibitor sensitivity factors and drug combinations Open
Durable control of invasive solid tumors necessitates identifying therapeutic resistance mechanisms and effective drug combinations. A promising approach to tackle the cancer drug resistance problem is to build mechanistic mathematical mod…
View article: Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance
Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance Open
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in childhood and adolescence. Refractory/relapsed RMS patients present a bad prognosis that combined with the lack of specific biomarkers impairs the development of new therapie…
View article: Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance
Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance Open
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in childhood and adolescence. Refractory/relapsed RMS patients present a bad prognosis that combined with the lack of specific biomarkers difficult the development of new therap…
View article: A New CDK9 Inhibitor on the Block to Treat Hematologic Malignancies
A New CDK9 Inhibitor on the Block to Treat Hematologic Malignancies Open
CDK9-specific inhibition with AZD4573 impairs cancer-promoting gene expression such as MCL-1 and has been proven effective in hematologic malignancies preclinical models. This new clinical candidate should be further explored in the clinic…